<DOC>
	<DOCNO>NCT00004156</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine immunization glycosylated MUC-1 antigen contain MUC-1 ( 106 ) MUC-1 ( 33 ) keyhole limpet hemocyanin conjugate plus immunological adjuvant QS21 induce antibody , helper T cell and/or cytotoxic T cell response MUC-1 patient high risk breast cancer express MUC-1 . OUTLINE : Patients receive glycosylated MUC-1 antigen contain MUC-1 ( 106 ) MUC-1 ( 33 ) keyhole limpet hemocyanin conjugate subcutaneously ( SQ ) plus immunological adjuvant QS21 SQ week 1-3 , 7 , 19 total 5 vaccination . Patients follow every 3 month . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed breast cancer high risk disease recurrence one follow requirement : Disease free stage IV breast cancer follow eradication disease surgery , radiotherapy , chemotherapy Stage I , II , III breast cancer remain clinically free identifiable disease follow adjuvant chemotherapy 2 consecutively rise CA15.3 ( BR2729 ) CEA level least 2 week apart Elevation marker level need stage III disease adjuvant therapy complete within past 2 year CEA increase least 1.5 time upper chronic value patient significant smoke history chronic CEA elevation le 15 Recurrence ipsilateral axilla follow lumpectomy/axillary dissection modify radical mastectomy Recurrence ipsilateral breast follow lumpectomy/axillary dissection Stage II disease least 4 positive axillary lymph node adjuvant therapy complete within past 2 year Stable stage IV disease hormonal therapy Colonoscopy require isolated CEA elevation Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 90100 % Life expectancy : Not specify Hematopoietic : Lymphocyte count least 500/mm3 WBC least 3,000/mm3 Hepatic : Alkaline phosphatase great 1.5 time upper limit normal ( ULN ) SGOT great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Other : No immunodeficiency autoimmune disease No seafood allergies No active malignancy except basal cell squamous cell skin cancer Not pregnant Negative pregnancy test Fertile patient must use effective barrier contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior immunotherapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>